Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Bharat Biotech Gets SEC Nod to Begin Phase III Trial of Inactivated Chikungunya Vaccine

Bharat Biotech dispatches three lakh doses of intranasal COVID vaccine to hospitals

Ruchika Sharma6 Feb 2023 10:00 AM IST

iNCOVACC is the world's first intranasal COVID-19 vaccine to receive approval for the primary 2-dose schedule, and as a heterologous booster dose for...

Natco Pharma gets approval for Everolimus tablets for Oral Suspension for subependymal giant cell astrocytoma

Natco Pharma gets 2 observations from USFDA for Vizag facility

Ruchika Sharma5 Feb 2023 1:00 PM IST

Hyderabad: Natco Pharma Limited has announced the completion of a regulatory inspection from the United States Food and Drug Administration (USFDA)...

Demand for affordable Indian generic vaccines skyrocket in China amid COVID surge

Ruchika Sharma5 Feb 2023 11:00 AM IST

Beijing: The world observed a brief pause in the Covid-19 insurgence after taking the vaccines, but it did not last for long. China reported a spike...

Japan's Takeda Pharma profit slips 13 percent, pipeline bolsters outlook

Ruchika Sharma5 Feb 2023 10:00 AM IST

The company said core operating profit, which strips out non-recurring items, increased 26 percent in the nine-month period.

USFDA nod to Takeda TAKHZYRO to prevent Hereditary Angioedema attacks in children 2 years of age and older

Ruchika Sharma4 Feb 2023 1:15 PM IST

Hereditary angioedema (HAE) is a rare genetic disorder that results in recurring attacks of edema - swelling - in various parts of the body, including...

India to spend USD 79.6 million to strengthen drug regulatory system: Health Minister

Ruchika Sharma4 Feb 2023 1:15 PM IST

Mandaviya said the federal government has allocated funds to his ministry for measures including setting up new drug testing laboratories and...

HIV drug kickbacks: Gilead Sciences to pay USD 202 million to settle lawsuit

Gilead Sciences secures USFDA okay for Trodelvy for pre-treated HR+/HER2- Metastatic Breast Cancer

Ruchika Sharma4 Feb 2023 11:37 AM IST

Trodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.

Sanofi Gets CDSCO Panel Nod to Update Prescribing Information for Xenpozyme

Sanofi forecasts moderate profit growth on eczema drug Dupixent demand

Ruchika Sharma4 Feb 2023 10:00 AM IST

Paris: Sanofi forecast moderate earnings growth that undershot expectations, saying demand for bestselling asthma and eczema drug Dupixent...

Central, state teams on way to Global Pharma Healthcare plant after firm recalls eye drop linked to vision loss in US

Ruchika Sharma4 Feb 2023 9:45 AM IST

The USFDA noted that the "use of contaminated Artificial Tears can result in the risk of eye infections that could result in blindness".

India hopes to conclude trade pact with US this year, finance minister says

Finance Minister announces launch of new programme to promote research in pharma

Ruchika Sharma3 Feb 2023 5:28 PM IST

Charu Sehgal, Partner, Deloitte India said," The announcement of providing investment and setting up centres of excellence to promote research and...

Zydus Lifesciences consolidated net profit rises 24.48 percent YoY to Rs 622.9 crore in Q3

Ruchika Sharma3 Feb 2023 3:28 PM IST

Total expenses in the third quarter were higher at Rs 3,620.7 crore, as compared to Rs 3,096.3 crore in the corresponding period last fiscal.

Siemens Healthineers Q1 profit slides on lower COVID test sales

Ruchika Sharma3 Feb 2023 2:15 PM IST

Revenues for the fiscal first quarter came to 5.08 billion euros, down 4.5 percent on a comparable basis, which was also below consensus for 5.21...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok